

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

JAN 16 1987

OFFICE OF  
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: EPA Reg. No. 359-686. Lindane: Review of a protocol for a 13 week dermal toxicity study with rabbits.

TOX CHEM No. 527  
TOX Project No. 7-0182  
Record No. 185400

FROM: John Doherty *John Doherty 1/13/87*  
Toxicology Branch  
Hazard Evaluation Division (TS-769)

TO: George LaRocca  
Product Manager 15  
Registration Division (TS-767)

THRU: Edwin Budd  
Section Head  
Toxicology Branch  
Hazard Evaluation Division (TS-769)

*Budd  
1/13/87*

THRU: Theodore Farber, Ph.D.  
Chief  
Toxicology Branch  
Hazard Evaluation Division (TS-769)

*Theodore M. Farber  
1/14/87*

Mr. Charles A. O'Connor of the law firm McKenna, Conner and Cupeo in a letter dated November 6, 1986 on behalf of their client Centre International d'Etudes du Lindane (CIEL) is requesting the Environmental Protection Agency to review a protocol for a rabbit 13 week dermal toxicity study with the insecticide lindane.

This study was previously requested by Toxicology Branch (TB) in order to assess potential toxicity via the dermal route to applicators and other individuals. The kidney and the blood (or bone marrow) may be potential targets for lindane and this study should be designed to assess these in particular as well as the usual parameters of a dermal toxicity study.

Overall Comments

[Note: Emphasis of this protocol review will be on aspects of the study related to particular problems associated with lindane. It is the registrants responsibility to submit studies otherwise consistent with current EPA Guidelines.]

Protocol Title: Lindane: 13 week dermal toxicity study (with interim kill and recovery period) in the rabbit.

Study Laboratory and authors: Hazleton UK (England), Protocol No. P3240d and HUK (HE?) Project No. 580/3.

Study director's name is illegible.

Dated October 22, 1986 (as authorized by sponsor).

The basic study plan consists of dosing 4 groups of 40 male and 40 female rabbits (New Zealand White) for up to 13 weeks with zero (control), and low, mid and high dose levels of lindane. The exact dose levels of lindane were not provided in the protocol. Ten males and ten females from each of the four dose groups will be sacrificed after six weeks of dosing. The main phase consisting of 20 males and 20 females from each dosage group will be sacrificed after 13 weeks of dosing. The recovery animals consisting of 10 male and 10 female rabbits per dose group will be sacrificed 42 days after (6 weeks) the last dermal application of lindane. This basic design, consisting of an interim sacrifice and a recovery period are acceptable to TB.

1. Dose level selection. Since the dose levels that will be used were not included, TB reminds the registrant that the high dose level should produce signs of systemic toxicity and not simply local reactions. The lowest dose level should demonstrate a NOEL for any resulting lesions (except irritation at the site of application).
2. Kidney assessment. Overall TB considers that the protocol is vague in describing the special aspects of the study which will assess for potential effects of lindane on the kidney.

Special aspects of the study that were mentioned in the protocol which attempt assess the kidney as a potential target organ for lindane include mechanically withdrawing the urine from the bladder and making three microscopic slides from each kidney. No special staining techniques were listed for use. Many parameters of the urinalysis are indicated as to be assessed semi-quantitatively but the procedure for semi-quantitative assessment was not described.

TB recommends that the protocol be rewritten to specifically address the problem of potential kidney toxicity and what will be done in this study with rabbits to determine if lindane causes the same type of kidney pathology responses noted in the subchronic rat study (Research and Consulting Co. Ltd, dated Feb. 3, 1983; see also TB review by Dr. K. Locke dated June 17, 1983).

3. Bone marrow and hematological assessment. No specific procedures were mentioned in the protocol which will attempt to assess for the potential for lindane to affect the composition of the bone marrow although mention is made that the bone marrow (femur and sternum) will be assessed.

TB recommends that the protocol be rewritten to include provisions which specifically address how bone marrow myelograms will be taken and prepared for microscopy (i.e. which stains will be used and which bone marrow elements will be quantitated).

4. TB notes that the protocol states that the lighting cycle will be "14 hours light and 12 hours dark". The light cycle should be 12 hours light and 12 hours dark.



# HAZLTON UK

Otley Road, Harrogate  
North Yorkshire HG3 1PY England

RECEIVED

OCT 27 1986

MARGARET McMULLEN

PROJECT TITLE

LINDANE :13 WEEK DERMAL TOXICITY STUDY (WITH INTERIM KILL AND RECOVERY PERIOD) IN THE RABBIT

PROTOCOL NUMBER

P3240d

HE PROJECT NUMBER

580/3

SPONSOR

Centre International d'Etudes du Lindane,  
250 Avenue Louise,  
BTE 72,  
B-1050 Bruxelles,  
BELGIUM.

signature

date

Issued by Study Director (or Deputy)

[Signature]

17 Oct 1986

Authorised for HUK Management by

G. Waite

17 October 1986

G. WAITE, CONTRACTS ADMINISTRATOR

\*Authorised for Sponsor by

[Signature]

22 Oct. 1986

Acknowledged and implemented  
by Study Director

\_\_\_\_\_  
\_\_\_\_\_

\*Instruction to Sponsor. Please type your name and company status underneath your signature, and return one signed copy to HUK as soon as possible.

Lindane toxicology review

---

Page \_\_\_\_\_ is not included in this copy.

Pages 5 through 20 are not included in this copy.

---

The material not included contains the following type of information:

- Identity of product inert ingredients
  - Identity of product impurities
  - Description of the product manufacturing process
  - Description of product quality control procedures
  - Identity of the source of product ingredients
  - Sales or other commercial/financial information
  - A draft product label
  - The product confidential statement of formula
  - Information about a pending registration action
  - FIFRA registration data
  - The document is a duplicate of page(s) \_\_\_\_\_
  - The document is not responsive to the request
- 

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

---